Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study sheds light on major bleeding in patients on common blood thinners

NCT ID NCT06147830

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at over 2,200 patients who had a major bleeding event while taking a Factor Xa inhibitor (a type of blood thinner). Researchers collected information on patient characteristics, how the bleeding was treated in the hospital, and what happened to patients afterward. The goal is to better understand these events and help improve care for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand how to treat major bleeding in patients taking Factor Xa inhibitors, potentially improving guidelines and patient outcomes.
What could go wrong
This is an observational study, not a clinical trial testing a new treatment. It describes what happened but does not prove that any specific intervention works better than another.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,202 people

The number who actually took part.

Started

Dec 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients aged ≥18 years admitted to hospital with an acute major bleeding or developed an acute bleeding while already in hospital and received ongoing treatment with a Factor Xa inhibitor before the index date.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years on the index date * Admitted to the hospital with an acute major bleeding or developed an acute bleeding while already in hospital * Ongoing treatment with a Factor Xa inhibitor before the index date * Provided signed and dated informed consent or able to obtain a waiver In addition, for cohort B: \- Administered reversal or replacement therapy Exclusion Criteria: * Pregnant women * Patients enrolled in any interventional trial that includes reversal/replacement agents In addition, for cohort B: * Use of vitamin K antagonists, dabigatran, prothrombin complex concentrates or recombinant factor VII, or transfusion of whole blood or plasma within the preceding 7 days of the index event * As judged by the investigator, if it is deemed undesirable for the patient to participate in the study or participant is unlikely to comply with study procedures, and requirements * Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major bleeding

Contacts and locations

Locations

  • Research Site

    Chandler, Arizona, 85224, United States

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    Sacramento, California, 95817, United States

  • Research Site

    Torrance, California, 90509, United States

  • Research Site

    Lakewood, Colorado, 80228-1527, United States

  • Research Site

    Hartford, Connecticut, 06102, United States

  • Research Site

    Orlando, Florida, 32803, United States

  • Research Site

    Tampa, Florida, 33606, United States

  • Research Site

    Glenview, Illinois, 60026, United States

  • Research Site

    Kansas City, Kansas, 66160, United States

  • Research Site

    Lexington, Kentucky, 40536, United States

  • Research Site

    Royal Oak, Michigan, 48073, United States

  • Research Site

    Kansas City, Missouri, 64111, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    Albany, New York, 12208, United States

  • Research Site

    New Hyde Park, New York, 11040, United States

  • Research Site

    Staten Island, New York, 10305, United States

  • Research Site

    Stony Brook, New York, 11794, United States

  • Research Site

    Valhalla, New York, 10595, United States

  • Research Site

    Chapel Hill, North Carolina, 27514, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Toledo, Ohio, 43614, United States

  • Research Site

    Portland, Oregon, 97201-3098, United States

  • Research Site

    Dallas, Texas, 75390, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

  • Research Site

    Aachen, Germany

  • Research Site

    Altenburg, Germany

  • Research Site

    Bad Neustadt/Saale, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Bochum, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Cologne, Germany

  • Research Site

    Dortmund, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Essen, Germany

  • Research Site

    G Ppingen, Germany

  • Research Site

    Jena, Germany

  • Research Site

    Koblenz, Germany

  • Research Site

    L Beck, Germany

  • Research Site

    L Neburg, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Ludwigshafen am Rhein, Germany

  • Research Site

    Osnabr Ck, Germany

  • Research Site

    Potsdam, Germany

  • Research Site

    Trier, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Asahikawa, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Hitachi, Japan

  • Research Site

    Izumo, Japan

  • Research Site

    Kagoshima, Japan

  • Research Site

    Kamakura, Japan

  • Research Site

    Kitakyushu, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Mitaka, Japan

  • Research Site

    Nagakute, Japan

  • Research Site

    Okayama, Japan

  • Research Site

    Saga, Japan

  • Research Site

    Shimotsuke, Japan

  • Research Site

    Suita, Japan

  • Research Site

    Tachikawa, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Aberdeen, United Kingdom

  • Research Site

    Bournemouth, United Kingdom

  • Research Site

    Canterbury, United Kingdom

  • Research Site

    Cardiff, United Kingdom

  • Research Site

    Edgbaston, United Kingdom

  • Research Site

    Harrow, United Kingdom

  • Research Site

    Liverpool, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Oxford, United Kingdom

  • Research Site

    Preston, United Kingdom

  • Research Site

    Sheffield, United Kingdom

  • Research Site

    Southampton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.